Inflammatory Bowel Disease (IBD) includes Crohn’s disease and Ulcerative Colitis (UC), which share similar clinical symptoms but result from different underlying pathologies. The mucosal immune system is inappropriately activated in response to antigens, leading to the inflammation associated with IBD. IBD has a multifactorial aetiology, with genetic, environmental, and immunological factors believed to play a role in its development and progression. At Epistem, we recognise the significance of using reliable and precise research models to advance our understanding of IBD and develop new therapeutic approaches. These models enable the assessment of novel drugs and therapies, offering valuable insights into disease mechanisms and potential treatment options.
Epistem’s preclinical models replicate aspects of IBD in humans and can be used to generate target validation and mechanism of action data to confirm the efficacy of novel therapeutic agents.
Epistem’s models of Inflammatory Bowel Disease:
• DSS-Induced Acute and Chronic Mediated Colitis
• Adoptive T-cell Transfer Mediated Colitis
• IL-10 knockout spontaneous colitis
• Bespoke Colitis Models
